Yes, the market for RSV is very significant, never mind the potential for NVAX to supplant the leaders in the flu vaccine industry. I can't wait for their combo respiratory vaccine (RSV plus quadrivalent seasonal flu). Plus, they can get vaccine made 90 days after viral genome coded. They can respond to pandemics like none other.
News 
Market Data 
Discover 
